And… We’re Back: The Reemergence of CD137 in Cancer Immunotherapy via Antigen Anchoring
Drug development targeting CD137 has been historically fraught because of concerns over safety and efficacy. A deeper understanding of CD137 function and insights into why earlier CD137 agonists failed have set the stage for a new generation of promising CD137 therapeutics. See related article by de Bono et al., p. 3388.
Authors
- Matthew K. Nguyen
- Jason J. Luke (ORCID: https://orcid.org/0000-0002-1182-4908)
Institutions
- University of Pittsburgh (US)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1089
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00